The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.
Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...
The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...
Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026).
The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.
Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results